SCHEDULE 13G/A: Context Therapeutics Insider Holdings Update: Martin Lehr and Trust Disclose Beneficial Ownership
Beneficial Ownership Disclosure
An amended Schedule 13G filing reveals the current beneficial ownership stakes of Martin Lehr, the Martin Lehr 2000 Trust, and Ellyn Lehr in Context Therapeutics Inc. as of December 31, 2024.
Summary
- Martin Lehr beneficially owns an aggregate of 1,595,742 shares of Context Therapeutics Inc. common stock, representing 2.1% of the class.
- Mr. Lehr's ownership includes 775,552 shares with sole voting and dispositive power (comprising 615,851 option shares exercisable within 60 days and 159,701 directly held shares).
- Mr. Lehr also has shared voting and dispositive power over 820,190 shares held by the Martin Lehr 2000 Trust.
- The Martin Lehr 2000 Trust beneficially owns 820,190 shares, representing 1.1% of the class, with shared voting and dispositive power.
- Ellyn Lehr beneficially owns 820,190 shares, representing 1.1% of the class, with shared voting and dispositive power, all held through the Martin Lehr 2000 Trust.
- The ownership percentages are calculated based on 74,998,312 shares of common stock outstanding as of November 4, 2024, as reported in the Issuer's Form 10-Q filed on November 6, 2024, plus Martin Lehr's exercisable option shares.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, providing no positive or negative operational or financial news, thus maintaining a neutral sentiment.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of beneficial ownership by an insider and related entities, common in the public markets. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: Provides transparency regarding the ownership stake of a key insider and related entities, which can be relevant for corporate governance and understanding insider alignment.
Key Dates
| Date | Description |
|---|---|
| 2024-11-04 | Date as of which 74,998,312 shares of Context Therapeutics Inc. common stock were outstanding, as reported in the Issuer's Quarterly Report on Form 10-Q. |
| 2024-11-06 | Date Context Therapeutics Inc. filed its Quarterly Report on Form 10-Q with the SEC. |
| 2024-12-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-02-12 | Signature date of the Schedule 13G filing by Martin Lehr, Martin Lehr 2000 Trust, and Ellyn Lehr. |
Keywords
Context Therapeutics Inc., Martin Lehr, Beneficial Ownership, Schedule 13G, SEC Filing, Common Stock, Insider Holdings, Trust Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.